Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 6/20 | 0.64 |
| ▸ | MMP2 | P08253 | 6/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | FABP4 | P15090 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.42 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882077 | 1.00 | MMP9 (0.64) | MMP9MMP2RAB9AFABP4CA1 | |
| SCHEMBL4599857 | 0.83 | MMP2 (0.67) | MMP9MMP2RAB9ACA1CA2 | |
| SCHEMBL4599862 | 0.83 | MMP2 (0.67) | MMP9MMP2RAB9ACA1CA2 | |
| SCHEMBL6562692 | 0.82 | MMP9 (0.87) | MMP9MMP2MMP8MMP13ADAMTS4 | |
| SCHEMBL6562688 | 0.82 | MMP9 (0.87) | MMP9MMP2MMP8MMP13ADAMTS4 | |
| SCHEMBL4599870 | 0.80 | MMP2 (0.56) | MMP9MMP2RAB9ACA1CA2 | |
| SCHEMBL4599874 | 0.80 | MMP2 (0.56) | MMP9MMP2RAB9ACA1CA2 | |
| SCHEMBL10585071 | 0.78 | MMP9 (0.76) | MMP9MMP2CA1CA2MMP8 | |
| SCHEMBL457772 | 0.78 | MMP9 (0.76) | MMP9MMP2CA1CA2MMP8 | |
| SCHEMBL8001084 | 0.78 | MMP9 (0.76) | MMP9MMP2CA1CA2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | MMP9 1398/4885MMP2 1319/4885RAB9A 649/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | MMP9 1098/4885MMP2 745/4885RAB9A 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.